News | April 05, 2013

Cardiac Electrical Biomarker Demonstrates Strong Correlation to High Sensitivity Troponin To Rule Out Acute Myocardial Ischemic Injury

April 5, 2013 — One of the leading complaints in the emergency department is chest pain and the timely detection of a heart attack is essential. The Johns Hopkins Hospital presented an abstract at the American College of Cardiology (ACC) conference in March that utilized VentraCor's VectraplexECG System. The abstract, entitled "New Cardiac Electrical Biomarker Measured on 12-Lead ECG Strongly Correlates With High Sensitivity Troponin in Patients Admitted to the Emergency Department to Rule Out Acute Myocardial Ischemic Injury," was presented by Larisa Tereshchenko, M.D., Ph.D., FAHA, of The Johns Hopkins Hospital.

The VectraplexECG System incorporates a novel biomarker, the Cardiac Electrical Biomarker (CEB), which in real-time, detects ECG changes suggestive of an acute myocardial infarction (AMI/heart attack). The CEB is an easy-to-read index number that will continuously display as the patient is monitored, potentially leading to faster treatment and clinician intervention for patients in the emergency department.

Data was analyzed on 130 patients, participants of a prospective cohort study, admitted to the emergency department (ED) to rule out acute myocardial infarction. Overall, 475 ECGs and 489 high sensitivity troponin (HST) measurements were included in the analysis. The CEB showed a strong, positive correlation with (HST) (r=0.560; P=0.0007).

"VectraCor is very excited about the data Johns Hopkins has presented and that our CEB shows a strong correlation to high sensitivity troponin," said Brad S. Schreck, president and CEO of VectraCor. He added, "Our technology is an exciting, non-invasive, real-time technology that will benefit many patients and may help clinicians diagnose more quickly the number one disease in the world."

"In this study we ran a completely blinded analysis of electrocardiograms. The strong correlation between VectraCor's CEB and troponin in a multivariate analysis (after adjustment for other clinical and demographic characteristics of patients) was very impressive. Future use of the VectraplexECG System with CEB holds big promise," stated Tereshchenko.

The current gold standard for AMI detection is a long process which can continue up to 24 hours and involves placing 10 electrodes to produce a 12-lead ECG and measuring cardiac serum biomarkers (i.e. troponin) every three to six hours via invasive blood draws. The VectraplexECG System (FDA-cleared/CE marked) uses only five electrodes to detect ECG changes suggestive of AMI and derives a 15-lead ECG (U.S.) and the 22-lead ECG (EU). This will give the clinician more information with fewer electrodes, while potentially reducing lead placement error.

For more information:

Related Content

ECG Study of NBA Players Shows Need for Sport-Specific Normative Data and Guidelines
News | ECG | December 08, 2017
Cardiologists at NewYork-Presbyterian/Columbia University Irving Medical Center compared electrocardiographic findings...
HeartSciences Announces CE Mark and European Launch of MyoVista High Sensitivity ECG

Just as a Doppler radar color image shows the energy of a storm, MyoVista provides physicians a detailed visual image of the energy distribution during the cardiac cycle.

News | ECG | August 22, 2017
HeartSciences announced the European launch of the MyoVista high sensitivity electrocardiograph (hsECG) Testing Device...
AUM Cardiovascular Receives FDA Approval for CADence ECG Device
Technology | ECG | August 08, 2017
AUM Cardiovascular announced it has received clearance from the U.S. Food and Drug Administration (FDA) for CADence, a...
More Than 20 Percent of Low-Risk Patients Receive Annual ECG
News | ECG | July 20, 2017
July 20, 2017 — More than one in five Ontario patients receive an ...
Heart Test Laboratories, HTL, MyoVista ECG, common stock offering
News | ECG | January 31, 2017
Heart Test Laboratories Inc. (HTL) has successfully raised $12 million by way of a Common Stock private placement...
AirStrip One, ECG management, web client, U.S. clearance
Technology | ECG | October 11, 2016
The U.S. Food and Drug Administration (FDA) has issued 510(K) Class II clearance to a web client for the AirStrip One...
Carestream, Vue Motion universal viewer, ECG waveforms, diagnostic reading, FDA clearance

Image courtesy of Carestream Health

Technology | ECG | November 20, 2015
Carestream has obtained U.S. Food and Drug Administration (FDA) clearance for diagnostic reading of electrocardiogram (...
CardioSecur mobile ECG, 22-lead, 360 degree view of the heart, CardioSecur Pro

Image courtesy of CardioSecur

Technology | ECG | October 08, 2015
Personal MedSystems introduced the first and only 22-lead mobile electrocardiogram (ECG) system, CardioSecur, at the...
Mortara, ELI 280, TouchScreen ECG, ECG advances, new ECG technology

The Mortara Eli 280 is part of a new generation of ECG systems that integrate touchscreen monitors to improve workflow.

Feature | ECG | September 16, 2015 | Dave Fornell
The resting electrocardiogram (ECG) has been us
zebrafish, iWorx Systems Inc., ZS-200 Zebrafish ECG System, cardiac research
Technology | ECG | August 13, 2015
iWorx Systems Inc., developer of advanced physiology teaching and research instruments and software, has introduced a...
Overlay Init